JP Morgan Chase
ESPR

JP Morgan Chase’s Esperion Therapeutics ESPR Stock Holding History

JP Morgan Chase’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,000
Closed -$56K – 6560
2022
Q1 		$56K Buy
+12,000
New +$51.5K ﹤0.01% 5756
2020
Q3 		– Sell
-129,300
Closed -$6.63M – 5542
2020
Q2 		$6.63M Buy
+129,300
New +$5.41M ﹤0.01% 2240
2018
Q3 		– Sell
-84,000
Closed -$3.29M – 5705
2018
Q2 		$3.29M Buy
+84,000
New +$4.24M ﹤0.01% 3011
2018
Q1 		– Sell
-45,000
Closed -$2.96M – 5454
2017
Q4 		$2.96M Buy
+45,000
New +$2.42M ﹤0.01% 3069

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

JP Morgan Chase's ESPR Position: Q2 2026 in Review

JP Morgan Chase increased its Esperion Therapeutics (ESPR) stake by 104% in Q2 2026, buying an estimated $1.99M and bringing the position to 1,396,857 shares worth $4.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3568.

JP Morgan Chase first reported a position in ESPR in Q1 2015 and has held it in 45 quarters since. The position peaked at $17.8M in Q1 2018. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • JP Morgan Chase held 1,396,857 shares of Esperion Therapeutics worth $4.4M as of Q2 2026.
  • JP Morgan Chase bought 711,191 Esperion Therapeutics shares in Q2 2026, an estimated $1.99M.
  • Esperion Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3568 holding.
  • JP Morgan Chase first reported a position in Esperion Therapeutics in Q1 2015 and has held it in 45 quarters since.
  • JP Morgan Chase's Esperion Therapeutics position peaked at $17.8M in Q1 2018.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.